Early-onset Alzheimer’s disease progresses more rapidly and often strikes people in the prime of their lives. A new treatment ...

Randall Bateman, MD, Charles F and Joanne Knight Distinguished Professor of Neurology at WashU Medicine. A study of Roche's anti-amyloid drug gantenerumab has suggested that early treatment to ...

For cognitively healthy people who carried an autosomal dominant AD mutation, eight years of treatment with gantenerumab halved the odds of developing symptoms. A preliminary analysis was presented at ...

The study evaluated Roche’s gantenerumab in 73 participants aged between 30 to 50 with rare, inherited genetic mutations that cause the overproduction of amyloid in the brain, which ...

"I am highly optimistic now, as this could be the first clinical evidence of what will become preventions for people at risk for Alzheimer's disease." HealthDay News — For individuals with ...

A recent study tests a new drug, gantenerumab on people with a genetically inherited form of Alzheimer’s disease. For people with this condition, dementia is almost inevitable. Gantenerumab ...

Get Instant Summarized Text (Gist) A long-term trial of gantenerumab for dominantly inherited Alzheimer's disease was halted due to safety concerns, including brain bleeding and swelling. Although ...

For 22 of the participants who received a drug called gantenerumab for eight years, their risk of developing symptoms was cut in half — from 100% to 50% — the researchers reported.